Synergistic Cytotoxicity of Perifosine and ABT-737 to Colon Cancer Cells

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2022 Dec 16

PMID 36523175

Authors

Barbora Adamova

Kamila rihova

Jana Pokludova

Petr Benes

Jan Smarda

Jarmila Navratilova

Affiliations

Soon will be listed here.

Abstract

An acidic environment and hypoxia within the tumour are hallmarks of cancer that contribute to cell resistance to therapy. Deregulation of the PI3K/Akt pathway is common in colon cancer. Numerous Akt-targeted therapies are being developed, the activity of Akt-inhibitors is, however, strongly pH-dependent. Combination therapy thus represents an opportunity to increase their efficacy. In this study, the cytotoxicity of the Akt inhibitor perifosine and the Bcl-2/Bcl-xL inhibitor ABT-737 was tested in colon cancer HT-29 and HCT-116 cells cultured in monolayer or in the form of spheroids. The efficacy of single drugs and their combination was analysed in different tumour-specific environments including acidosis and hypoxia using a series of viability assays. Changes in protein content and distribution were determined by immunoblotting and a "peeling analysis" of immunohistochemical signals. While the cytotoxicity of single agents was influenced by the tumour-specific microenvironment, perifosine and ABT-737 in combination synergistically induced apoptosis in cells cultured in both 2D and 3D independently on pH and oxygen level. Thus, the combined therapy of perifosine and ABT-737 could be considered as a potential treatment strategy for colon cancer.

Citing Articles

Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes.

Xiong J, Dong L, Lv Q, Yin Y, Zhao J, Ke Y Clin Transl Med. 2024; 14(9):e1772.

PMID: 39270064 PMC: 11398298. DOI: 10.1002/ctm2.1772.

ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells.

Li X, Guo Y, Xing Z, Gong T, Yang L, Yang T Oncol Rep. 2024; 52(3).

PMID: 39054955 PMC: 11292299. DOI: 10.3892/or.2024.8781.

The combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis.

Zhao W, Zhou L, Zhao W, Yang H, Lu Z, Zhang L Cell Death Discov. 2024; 10(1):315.

PMID: 38977680 PMC: 11231210. DOI: 10.1038/s41420-024-02085-1.

Mitochondrial Functionality Is Regulated by Alkylphospholipids in Human Colon Cancer Cells.

Torrens-Mas M, Collado-Sole A, Sola-Leyva A, Paz Carrasco-Jimenez M, Oliver J, Pons D Biology (Basel). 2023; 12(12).

PMID: 38132283 PMC: 10740929. DOI: 10.3390/biology12121457.

Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.

Xu J, Dong X, Huang D, Xu P, Zhao Q, Chen B Cancers (Basel). 2023; 15(20).

PMID: 37894324 PMC: 10605442. DOI: 10.3390/cancers15204957.

References

Michalek J, Stepka K, Kozubek M, Navratilova J, Pavlatovska B, Machalkova M . Quantitative Assessment of Anti-Cancer Drug Efficacy From Coregistered Mass Spectrometry and Fluorescence Microscopy Images of Multicellular Tumor Spheroids. Microsc Microanal. 2019; 25(6):1311-1322. DOI: 10.1017/S1431927619014983. View

Vaupel P, Thews O, Hoeckel M . Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2002; 18(4):243-59. DOI: 10.1385/MO:18:4:243. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Feng L, Li M, Liu Y, Yang S, Zhang N . Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int J Mol Sci. 2014; 15(3):4201-20. PMC: 3975392. DOI: 10.3390/ijms15034201. View

Machalkova M, Pavlatovska B, Michalek J, Pruska A, Stepka K, Necasova T . Drug Penetration Analysis in 3D Cell Cultures Using Fiducial-Based Semiautomatic Coregistration of MALDI MSI and Immunofluorescence Images. Anal Chem. 2019; 91(21):13475-13484. DOI: 10.1021/acs.analchem.9b02462. View

Locatelli S, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A . Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia. 2013; 27(8):1677-87. DOI: 10.1038/leu.2013.28. View

Navratilova J, Karasova M, Lanova M, Jirakova L, Budkova Z, Pachernik J . Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate. J Cell Mol Med. 2017; 21(9):1859-1869. PMC: 5571524. DOI: 10.1111/jcmm.13106. View

Song J, Kandasamy K, Zemskova M, Lin Y, Kraft A . The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2010; 71(2):506-15. PMC: 3459262. DOI: 10.1158/0008-5472.CAN-10-1977. View

Tahir S, Yang X, Anderson M, Morgan-Lappe S, Sarthy A, Chen J . Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007; 67(3):1176-83. DOI: 10.1158/0008-5472.CAN-06-2203. View

10.

Song Z, Tu X, Zhou Q, Huang J, Chen Y, Liu J . A novel UCHL inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair. Cell Death Dis. 2019; 10(6):398. PMC: 6529448. DOI: 10.1038/s41419-019-1628-8. View

11.

Ryder C, McColl K, Zhong F, Distelhorst C . Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk. J Biol Chem. 2012; 287(33):27863-75. PMC: 3431637. DOI: 10.1074/jbc.M112.384685. View

12.

Richardson P, Eng C, Kolesar J, Hideshima T, Anderson K . Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5):623-33. PMC: 4467022. DOI: 10.1517/17425255.2012.681376. View

13.

Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V . 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018; 14(4):910-919. PMC: 6040128. DOI: 10.5114/aoms.2016.63743. View

14.

Souza A, Silva I, Campos-Fernandez E, Barcelos L, Souza J, Marangoni K . Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response. Curr Pharm Des. 2018; 24(15):1689-1694. DOI: 10.2174/1381612824666180404152304. View

15.

Tagscherer K, Fassl A, Campos B, Farhadi M, Kraemer A, Bock B . Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008; 27(52):6646-56. DOI: 10.1038/onc.2008.259. View

16.

Wojtkowiak J, Verduzco D, Schramm K, Gillies R . Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011; 8(6):2032-8. PMC: 3230683. DOI: 10.1021/mp200292c. View

17.

Howard A, Bridges K, Meyn R, Chandra J . ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. Cancer Chemother Pharmacol. 2009; 65(1):41-54. DOI: 10.1007/s00280-009-1001-1. View

18.

Adamova B, rihova K, Pokludova J, Benes P, Smarda J, Navratilova J . Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells. J Cell Mol Med. 2022; 27(1):76-88. PMC: 9806293. DOI: 10.1111/jcmm.17636. View

19.

Liu Q, Turner K, Yung W, Chen K, Zhang W . Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol. 2014; 16(10):1313-23. PMC: 4165418. DOI: 10.1093/neuonc/nou058. View

20.

Opydo-Chanek M, Rak A, Cierniak A, Mazur L . Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Toxicol In Vitro. 2017; 42:38-46. DOI: 10.1016/j.tiv.2017.03.013. View